References
- Marasca C, Ruggiero A, Annunziata MC, et al. Face the COVID-19 emergency: measures applied in an Italian dermatologic clinic. J Eur Acad Dermatol Venereol. 2020. DOI:https://doi.org/10.1111/jdv.16476
- Conforti C, Giuffrida R, Dianzani C, et al. COVID-19 and psoriasis: is it time to limit treatment with immunosuppressants? A call for action. Dermatol Ther. 2020;e13298. DOI:https://doi.org/10.1111/dth.13298
- Bardazzi F, Loi C, Sacchelli L, et al. A. Biologic therapy for psoriasis during the covid-19 outbreak is not a choice. J Dermatolog Treat. 2020;31(4):320–321.
- Megna M, Ruggiero A, Marasca C, et al. Biologics for psoriasis patients in the COVID-19 era: more evidence, less fears. J Dermatolog Treat. 2020;31(4):328–329.
- Carugno A, Raponi F, Locatelli AG, et al. P. No evidence of increased risk for COVID-19 infection in patients treated with Dupilumab for atopic dermatitis in a high-epidemic area – Bergamo, Lombardy, Italy. J Eur Acad Dermatol Venereol. 2020. DOI:https://doi.org/10.1111/jdv.16552
- Ferrucci S, Romagnuolo M, Angileri L, et al. Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: two case reports. J Eur Acad Dermatol Venereol. 2020. DOI:https://doi.org/10.1111/jdv.16527
- Megna M, Napolitano M, Fabbrocini G. May IL-17 have a role in COVID-19 infection? Med Hypotheses. 2020;140:109749.
- Eichenfield LF, Bieber T, Beck LA, et al. Infections in dupilumab clinical trials in atopic dermatitis: a comprehensive pooled analysis. Am J Clin Dermatol. 2019;20(3):443–456.
- Li CK, Wu H, Yan H, et al. T cell responses to whole SARS coronavirus in humans. J Immunol. 2008;181(8):5490–5500.
- Megna M, Napolitano M, Patruno C, et al. Biologics for psoriasis in COVID-19 era: what do we know? Dermatol Ther. 2020;e13467. DOI:https://doi.org/10.1111/dth.13467
- Patruno C, Stingeni L, Fabbrocini G, et al. Dupilumab and COVID-19: what should we expect? 2020;e13502. DOI:https://doi.org/10.1111/dth.13502